AustralianSuper’s Regeneron Pharmaceuticals REGN Stock Holding History

AustralianSuper’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-678	Closed	-$430K	–	282
2025 Q1	$430K	Buy	+678	New	+$466K	﹤0.01%	227
2023 Q3	–	Sell	-855	Closed	-$614K	–	274
2023 Q2	$614K	Sell	855 -117,164	-99%	-$90.3M	﹤0.01%	243
2023 Q1	$97M	Buy	118,019 +1,424	+1%	+$1.07M	0.59%	44
2022 Q4	$84M	Sell	116,595 -14,374	-11%	-$10.6M	0.56%	51
2022 Q3	$90.2M	Buy	130,969 +66,692	+104%	+$42M	0.64%	40
2022 Q2	$38M	Buy	+64,277	New	+$41.8M	0.23%	86
2021 Q4	–	Sell	-75,725	Closed	-$45.8M	–	190
2021 Q3	$45.8M	Sell	75,725 -10,450	-12%	-$6.49M	0.29%	63
2021 Q2	$48.1M	Buy	86,175 +15,684	+22%	+$7.95M	0.34%	57
2021 Q1	$33.4M	Buy	70,491 +54,096	+330%	+$26.3M	0.26%	71
2020 Q4	$7.92M	Buy	+16,395	New	+$8.85M	0.06%	91
2020 Q3	–	Sell	-6,015	Closed	-$3.75M	–	186
2020 Q2	$3.75M	Buy	+6,015	New	+$3.41M	0.04%	142

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AustralianSuper's REGN Position: Q2 2025 in Review

AustralianSuper sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 678 shares — an estimated $430K sold.

AustralianSuper first reported a position in REGN in Q2 2020 and held it in 11 quarters. The position peaked at $97M in Q1 2023. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

AustralianSuper reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
AustralianSuper sold 678 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $430K.
AustralianSuper first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 11 quarters.
AustralianSuper's Regeneron Pharmaceuticals position peaked at $97M in Q1 2023.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on AustralianSuper's 13F filing for Q2 2025, filed 1 Aug 2025.